Tactile Medical Reports Q3 Revenue Growth and Provides 2026 EBITDA Guidance
Tactile Systems Technology, Inc. (TCMD) reported third-quarter revenue of $91.9 million, driven largely by a 13% year-over-year increase in its lymphedema segment. This performance marks the company's fifth consecutive quarter of achieving double-digit growth that exceeds market averages. Looking ahead to 2026, management has provided long-term financial guidance, targeting an adjusted EBITDA between $50 million and $52 million. The company also maintained its revenue outlook for the same period, projecting figures in the range of $360 million to $366 million.
Tickers: $TCMD
Topics: earnings report lymphedema treatment revenue growth
Read the full article at Seeking Alpha
Part of the story Aflac Reports Third Quarter 2026 Results and Declares Fourth Quarter Dividend (25 articles)